Optimizing ALA-PDT in the management of non-melanoma skin cancer by fractionated illumination.
The aim of this review was to describe briefly the mechanism and history of photodynamic therapy (PDT). The achieved preclinical and clinical results in Rotterdam are discussed in the light of a search to optimize aminolevulinic acid-photodynamic therapy (ALA-PDT). As the incidence of skin cancer is rising, an optimized treatment in non-melanoma skin cancer is needed.
De Vijlder
H C
HC
Department of Dermatology, Erasmus MC University Hospital, Rotterdam, The Netherlands.
Middelburg
T
T
De Bruijn
H S
HS
Martino Neumann
H A
HA
Sterenborg
H C J M
HC
Robinson
D J
DJ
De Haas
E R M
ER
D000622:Aminolevulinic Acid / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*
D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid